LEXX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Lexaria Bioscience Corp (LEXX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance is extremely poor, with significant declines in revenue, net income, EPS, and gross margin. Technical indicators are mixed, with a neutral RSI and bearish MACD, despite bullish moving averages. Additionally, there are no positive news catalysts, no significant trading trends, and no proprietary trading signals to support a buy decision. The lack of congressional trading data and options data further reduces confidence in the stock.
The MACD is bearish with a negatively expanding histogram (-0.00815). RSI is neutral at 44.399, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). Key support and resistance levels are: Pivot: 0.971, R1: 1.043, S1: 0.899, R2: 1.087, S2: 0.854.
NULL identified.
Significant declines in financial performance metrics, including revenue (-100% YoY), net income (-41.01% YoY), EPS (-56.25% YoY), and gross margin (-100% YoY). No recent news, no trading trends, and no congressional trading data.
In Q1 2026, revenue dropped to 0 (-100% YoY), net income dropped to -$1,595,007 (-41.01% YoY), EPS dropped to -0.07 (-56.25% YoY), and gross margin dropped to 0 (-100% YoY).
No analyst rating or price target changes available.
